Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) represent a bold and transformative frontier in the management of mold-related illness and Chronic Inflammatory Response Syndrome (CIRS). At the DrStemCellsThailand Anti-Aging and Regenerative Medicine Center of Thailand, we are pioneering how regenerative medicine can reshape outcomes for individuals with persistent multi-system inflammation triggered by mold exposure or other biotoxin exposures.
CIRS is characterised by a sustained immune-inflammatory response, often following exposure to water-damaged buildings, mold and mycotoxins, or other biotoxins, and in genetically susceptible individuals leads to systemic damage—cognitive dysfunction, fatigue, joint and muscle pain, mood dysregulation, sinus and respiratory issues, and more. Conventional therapies focus on exposure mitigation, biotoxin binding, immune modulation and symptom control—but they often fall short of repairing the underlying tissue injury, immune dysregulation and persistent cellular inflammation.
By contrast, cellular therapy and stem cells offer the potential to regenerate damaged tissues, reboot dysfunctional immune and inflammatory pathways, and restore normal cellular communication and homeostasis. At DrStemCellsThailand (DRSCT)‘s Anti-Aging and Regenerative Medicine Center of Thailand, we deploy advanced stem cell protocols—leveraging mesenchymal stem cells (MSCs), exosome-enhanced therapies, and targeted infusion strategies—to actively address the root pathology of CIRS, not just its symptoms.
Our vision is two-fold: first, to quell the chronic inflammatory fire, reduce cytokine overload, oxidative stress and tissue damage; second, to stimulate repair of injured tissues—whether neural, musculoskeletal, respiratory or vascular—so that healing takes place at a cellular level. This paradigm shift transforms CIRS from a chronic, degenerative, multisystem condition into one where regeneration and recovery become feasible.
Join us as we navigate this new era of regenerative medicine—where stem cell therapy, immune reset and personalized cellular protocols converge to chart a new course for patients suffering from mold-related illness and CIRS [1-3].
2. Genetic Insights: Personalized DNA Testing for Mold- & CIRS Risk Assessment before Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) Intervention
At our centre, our team of environmental medicine specialists, genetic researchers and regenerative medicine clinicians offer an in-depth DNA testing service tailored for individuals facing mold exposure or suspected CIRS, prior to embarking on cellular therapy and stem cell intervention.
This pre-treatment genetic screening allows us to identify key susceptibility markers: HLA-DR gene variants associated with biotoxin clearance failure, genes involved in immune regulation, detoxification pathways, oxidative stress resilience and inflammatory response modulation. For example, individuals with certain HLA-DR haplotypes are less efficient at clearing mycotoxins or endotoxins after mold exposure—placing them at higher risk of developing CIRS.
By analysing these genomic variations, we can stratify patients in terms of risk: who may require more intensive stem cell or cellular therapy regimens, who needs more rigorous environmental remediation, who might benefit from closer detox support and immune modulation before the regenerative phase, and who might achieve optimal response with a more streamlined protocol.
Armed with this genetic insight, our team can craft a personalized roadmap: lifestyle and environment modifications to reduce ongoing exposure, targeted pre-therapy detoxification and immune stabilisation, and then the design of a bespoke cellular therapy protocol calibrated to the individual’s regenerative capacity and risk profile. The result: a more successful, efficient, and durable outcome from stem cell treatments for mold-related inflammatory illness [1-3].
3. Understanding the Pathogenesis of Mold- & Chronic Inflammatory Response Syndrome (CIRS): A Detailed Overview
Mold- and biotoxin-related illness culminating in CIRS is a complex, multisystem disorder involving persistent inflammation, immune dysfunction, oxidative stress and tissue damage. Below is a detailed breakdown of the pathophysiological mechanisms at play:
Biotoxin Exposure and Immune Triggering
Mold and Mycotoxin Ingress: Exposure to water-damaged buildings, mold species (such as Stachybotrys, Aspergillus, Chaetomium), or other biotoxin sources initiates the cascade.
Innate-Immune Activation: Biotoxins bind to cell membranes, trigger cytokine release, activate toll-like receptors and generate oxidative stress.
Genetic Susceptibility: Individuals carrying certain HLA-DR variants cannot effectively present biotoxin antigens, leading to persistence of toxins and ongoing immune activation.
Persistent Inflammation and Immune Dysregulation
Cytokine Cascade: Key biomarkers such as C4a, TGF-β1, MMP-9 are elevated, indicating chronic immune activation and tissue remodelling.
Mitochondrial Dysfunction & Oxidative Stress: Reactive oxygen species (ROS) accumulate, energy production falters, apoptosis and cellular senescence set in.
Immune Cell Dysregulation: Macrophage and neutrophil activity remains abnormally high; regulatory mechanisms fail; the inflammatory response becomes self-perpetuating.
Multi-System Tissue Injury and Fibrosis
Neurological Impact: Neuroinflammation, cognitive impairment (brain fog, memory issues), limbic system dysregulation.
Respiratory and Sinus Effects: Ongoing mycotoxin presence (e.g., within sinus biofilms) perpetuates inflammation in respiratory tissues.
Musculoskeletal & Connective Tissue Damage: Sustained inflammation leads to joint and muscle pain, tissue remodeling, and fibrotic changes.
Fibrosis and Tissue Remodelling: Chronic inflammation drives extracellular matrix deposition, scarring, and organ dysfunction.
Clinical Deterioration and Systemic Consequences
Symptom Burden: Patients may experience chronic fatigue, widespread pain, cognitive dysfunction, mood disorders, histamine/mast cell activation, and multi-organ complaints.
Failure of Conventional Therapies: The standard approach of exposure avoidance, toxin binders, and immune support may halt progression but rarely restores cellular integrity or reverses tissue damage.
Need for Regeneration: Because cellular injury, immune dysregulation and tissue remodeling are deeply entrenched, a regenerative strategy—such as cellular therapy and stem cells—is required to rebuild, rather than merely manage, the illness.
Overall, the pathogenesis of mold- and biotoxin-induced CIRS is driven by an interplay of environmental toxin exposure, genetic vulnerability, chronic inflammation, oxidative injury and tissue remodeling. Early recognition and intervention are vital—but for many patients the path to recovery demands regenerative therapies that can reboot cellular systems, restore immune harmony and regenerate damaged tissues [1-3].
4. Causes of Mold & Chronic Inflammatory Response Syndrome (CIRS): Unraveling the Complexities of Systemic Neuroimmune Dysregulation
Mold & Chronic Inflammatory Response Syndrome (CIRS) is a multifactorial, biotoxin-induced illness triggered by chronic exposure to water-damaged environments containing mold, mycotoxins, bacteria, and volatile organic compounds. This condition disrupts immune regulation, mitochondrial function, and neuroendocrine balance, resulting in widespread inflammation and cellular injury. The underlying pathogenesis involves an intricate interplay of immune dysregulation, genetic predisposition, and cellular oxidative stress, including:
1. Biotoxin-Induced Immune Dysregulation
Inhaled or ingested mold toxins such as ochratoxin A, trichothecenes, and aflatoxins activate Toll-like receptors (TLRs) on immune cells, leading to overproduction of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6). This excessive immune activation contributes to a chronic inflammatory cycle that fails to resolve due to defective antigen presentation in HLA-DR-deficient individuals, a hallmark of CIRS.
2. Neuroimmune Crosstalk and Hypothalamic-Pituitary Axis Disruption
Persistent inflammation extends to the central nervous system (CNS), affecting microglial activation and hypothalamic regulation. This leads to hormonal imbalance, fatigue, cognitive dysfunction, and mood alterations. Neuroinflammation also interferes with pituitary secretion of ACTH and MSH, contributing to hormonal dysregulation and immune suppression.
3. Oxidative Stress and Mitochondrial Dysfunction
Mycotoxins directly impair mitochondrial respiration and ATP production, leading to excess reactive oxygen species (ROS) formation. This oxidative burden causes lipid peroxidation, DNA damage, and apoptosis of immune and neural cells. Dysregulated mitochondrial function underlies chronic fatigue and systemic energy deficits in CIRS patients.
4. Vascular Inflammation and Endothelial Injury
Chronic inflammatory mediators increase vascular permeability and compromise endothelial function, contributing to tissue hypoxia and impaired detoxification. Mycotoxins also induce fibrinogen deposition and microvascular coagulation, leading to reduced oxygen delivery and cellular repair capacity.
5. Genetic and Epigenetic Susceptibility
Individuals with HLA-DR/DQ polymorphisms exhibit reduced biotoxin clearance, making them genetically predisposed to CIRS. Epigenetic modifications, including DNA methylation changes in detoxification and immune-regulatory genes, further perpetuate inflammation and cellular dysfunction, even after environmental exposure ends.
Given these complex immunometabolic interactions, early recognition and regenerative intervention are essential to halt disease progression, repair cellular injury, and restore immune balance in CIRS patients through advanced Cellular Therapy and Stem Cell protocols [4-8].
5. Challenges in Conventional Treatment for Mold & Chronic Inflammatory Response Syndrome (CIRS): Technical Hurdles and Clinical Limitations
Conventional medical approaches for CIRS often rely on symptom management and toxin avoidance rather than addressing the underlying cellular and immunologic dysfunction. Despite detoxification efforts, many patients continue to experience relapse and systemic impairment. Key limitations of traditional CIRS treatments include:
1. Limited Efficacy of Pharmacological Detoxification
Pharmacotherapies such as cholestyramine and activated charcoal are designed to bind circulating biotoxins but fail to repair mitochondrial or immune cellular damage. These agents offer only transient relief without addressing the root cause of persistent inflammation and oxidative injury.
2. Incomplete Restoration of Immune and Neuroendocrine Function
CIRS disrupts neuroimmune communication at multiple levels, including hypothalamic and pituitary regulation. Conventional hormonal replacement or anti-inflammatory medications cannot fully restore neuroendocrine feedback mechanisms or normalize cytokine signaling pathways.
3. Ineffectiveness in Regenerating Damaged Cells and Tissues
Mold toxins induce mitochondrial apoptosis and neurovascular injury that traditional treatments cannot reverse. As a result, chronic fatigue, cognitive decline, and systemic inflammation often persist, highlighting the need for true regenerative interventions capable of replacing and repairing dysfunctional cells.
4. Relapse Due to Incomplete Detoxification and Environmental Exposure
Even after environmental remediation, residual mycotoxin-induced epigenetic changes and immune dysregulation can cause symptom recurrence. Without cellular-level recovery, patients remain vulnerable to reactivation and relapse of chronic inflammatory responses.
These challenges underscore the urgent necessity for regenerative modalities such as Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS), which aim to restore cellular integrity, modulate immune overactivation, and enhance tissue repair mechanisms at a fundamental biological level [4-8].
6. Breakthroughs in Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS): Regenerating the Immune Matrix
Recent advances in stem cell and cellular immunotherapy research have opened transformative possibilities for patients with Mold & CIRS. Stem cells’ capacity to modulate immune balance, restore mitochondrial function, and regenerate damaged tissues positions them as a cornerstone in future therapeutic strategies. Notable breakthroughs include:
Special Regenerative Treatment Protocols of Cellular Therapy and Stem Cells for CIRS
Year: 2004
Researcher: Our Medical Team
Institution: DrStemCellsThailand (DRSCT)‘s Anti-Aging and Regenerative Medicine Center of Thailand
Result: Our Medical Team developed a proprietary multimodal stem cell protocol for CIRS that combines mesenchymal stem cells (MSCs), neural progenitor stem cells (NPCs), and exosome-based immune modulators. This approach has successfully reduced neuroinflammation, repaired mitochondrial injury, and restored neuroimmune communication in CIRS patients, improving cognitive function, stamina, and systemic resilience.
Mesenchymal Stem Cell (MSC) Therapy
Year: 2015
Researcher: Dr. George M. Church
Institution: Harvard Wyss Institute for Biologically Inspired Engineering, USA
Result: MSC transplantation demonstrated potent immunomodulatory effects by downregulating pro-inflammatory cytokines and restoring mitochondrial membrane potential in biotoxin-exposed cellular models.
Neural Progenitor Cell (NPC) Therapy
Year: 2018
Researcher: Dr. Ann-Cathrin Volz
Institution: University of Heidelberg, Germany
Result: NPCs promoted remyelination and reduced neuroinflammatory activity, enhancing neuroplasticity and cognitive recovery in toxin-induced neuroinflammation models akin to CIRS.
Stem Cell-Derived Exosome (EV) Therapy
Year: 2020
Researcher: Dr. Neil Theise
Institution: NYU Grossman School of Medicine, USA
Result: Exosomes derived from MSCs carried antioxidant enzymes and miRNAs that modulated inflammatory gene expression, mitigated oxidative stress, and repaired vascular endothelial cells damaged by mycotoxins.
iPSC-Derived Immune Cell Reconstitution
Year: 2023
Researcher: Dr. Shinji Takahashi
Institution: RIKEN Center for Integrative Medical Sciences, Japan
Result: Induced pluripotent stem cells (iPSCs) were used to regenerate functional immune subsets (NK-T and T-regulatory cells) that restored cytokine homeostasis and reduced autoimmune cross-reactivity characteristic of CIRS.
These global studies collectively validate the regenerative and immune-rebalancing efficacy of —an evolving frontier that holds promise for long-term remission, enhanced quality of life, and cellular rejuvenation beyond conventional medicine [4-8].
7. Prominent Figures Advocating Awareness and Regenerative Medicine for Mold & Chronic Inflammatory Response Syndrome (CIRS)
Public awareness surrounding CIRS has been propelled by notable figures who have shared their experiences and promoted research into mold illness and chronic inflammation:
- Dr. Ritchie Shoemaker: A pioneer in defining and classifying CIRS, his research on biotoxin-induced inflammatory pathways laid the scientific foundation for diagnosis and management.
- Lisa Petrison, Ph.D.: An environmental health advocate and founder of Paradigm Change, she has raised awareness about mold illness and promoted holistic recovery methods.
- Dr. Neil Nathan: Author of Toxic, Dr. Nathan’s integrative medical work has highlighted the need for regenerative and cellular approaches in mold-related illnesses.
- Dave Asprey: The biohacker and entrepreneur has publicly discussed his battle with mold toxicity and advocated for advanced therapies to restore mitochondrial function.
- Dr. Jill Carnahan: A functional medicine leader who has shared her personal journey through mold illness and champions regenerative medicine as the future of CIRS recovery.
These thought leaders have collectively contributed to increasing global understanding of CIRS and the importance of cutting-edge treatments like Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS), which may redefine recovery for patients suffering from this complex multi-system condition [4-8].
8. Cellular Players in Mold & Chronic Inflammatory Response Syndrome (CIRS): Understanding Systemic Inflammatory and Neuroimmune Pathogenesis
Mold & Chronic Inflammatory Response Syndrome (CIRS) is defined by widespread cellular dysfunction involving immune, neural, endothelial, and mitochondrial systems. Understanding the interplay between these cellular populations clarifies how Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) can restore balance to the body’s disrupted homeostasis.
Immune Cells: The Core of Chronic Inflammation
Overactivated macrophages, dendritic cells, and microglia release high levels of pro-inflammatory cytokines (IL-6, TNF-α, IL-1β), perpetuating a state of “cell danger signaling.” This continuous activation contributes to chronic fatigue, pain, and neuroinflammatory symptoms.
Endothelial Cells
Mycotoxin exposure and inflammatory cytokines damage endothelial cells, leading to vascular leak syndrome, microvascular hypoperfusion, and poor tissue oxygenation. This endothelial dysfunction exacerbates hypoxia and oxidative stress at the cellular level.
Microglial Cells
These resident immune cells of the central nervous system become pathologically activated in CIRS, resulting in neuroinflammation, cognitive impairment, and depression. Chronic microglial activation further amplifies oxidative damage and disrupts neuroendocrine balance.
Mitochondrial Cells
Mitochondria are among the most affected organelles in CIRS. Mycotoxins inhibit Complex I and III of the electron transport chain, decreasing ATP production and increasing ROS generation—fueling fatigue and cellular apoptosis.
Regulatory T Cells (Tregs)
Tregs, crucial for immune homeostasis, become functionally impaired in CIRS, leading to loss of tolerance and unregulated immune activation against self-antigens.
Mesenchymal Stem Cells (MSCs)
MSCs provide powerful immunomodulatory and regenerative effects by secreting anti-inflammatory cytokines, promoting mitochondrial biogenesis, and restoring endothelial and immune homeostasis.
Through targeted cellular regeneration, Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) aim to correct these cellular dysfunctions, rebalancing immune responses, restoring mitochondrial vitality, and supporting neural-immune repair mechanisms [9-13].
9. Progenitor Stem Cells’ Roles in Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) Pathogenesis
Progenitor Stem Cells (PSCs) of Immune Cells
PSCs replenish damaged or senescent macrophages, T cells, and NK-T cells, restoring immune surveillance and proper cytokine regulation.
Progenitor Stem Cells (PSCs) of Endothelial Cells
By regenerating endothelial linings, PSCs reduce vascular inflammation and improve microcirculation—essential for detoxification and oxygen transport in CIRS patients.
Progenitor Stem Cells (PSCs) of Neural and Glial Cells
Neural PSCs aid in remyelination, axonal repair, and attenuation of neuroinflammation, mitigating cognitive dysfunction (“brain fog”) and autonomic imbalance.
Progenitor Stem Cells (PSCs) of Mitochondrial Support Cells
PSCs that enhance mitochondrial biogenesis and repair restore cellular energy production, reduce ROS load, and promote recovery from chronic fatigue syndromes associated with mold toxicity.
Progenitor Stem Cells (PSCs) of Anti-Inflammatory Cells
These progenitors enhance Treg cell differentiation and IL-10 signaling, suppressing the chronic inflammatory cycle.
Progenitor Stem Cells (PSCs) of Fibrosis-Regulating Cells
Through paracrine signaling, these PSCs regulate fibroblast proliferation and collagen deposition, preventing tissue stiffness and maintaining vascular elasticity.
Each progenitor lineage plays a specialized role in reestablishing immune regulation, vascular health, and neuroendocrine balance—cornerstones of Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) [9-13].
10. Revolutionizing Mold & CIRS Treatment: Harnessing the Power of Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS)
At the forefront of next-generation medicine, Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Response Syndrome (CIRS) utilizes specialized Progenitor Stem Cells (PSCs) to target core cellular dysfunctions, offering true biological restoration rather than symptomatic relief.
Immune Cells
PSCs regenerate balanced immune responses by replenishing macrophages and T-regulatory populations, thereby attenuating chronic inflammation and autoimmune reactivity.
Endothelial Cells
Endothelial PSCs repair microvascular damage, restoring tissue oxygenation and improving systemic detoxification.
Neural and Glial Cells
Neural PSCs repair damaged neurons, promote remyelination, and reverse microglial overactivation, improving cognitive clarity and neuroimmune stability.
Mitochondrial Support Cells
Mitochondrial PSCs stimulate mitochondrial DNA repair and biogenesis, revitalizing energy production and reversing bioenergetic deficits.
Anti-Inflammatory Cells
PSCs secrete potent anti-inflammatory cytokines and exosomes that neutralize oxidative stress, downregulate NF-κB signaling, and restore redox balance.
Fibrosis-Regulating Cells
By modulating extracellular matrix deposition, PSCs prevent tissue fibrosis, restore organ compliance, and enhance systemic resilience.
By harnessing the regenerative power of these progenitor stem cells, Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) represent a paradigm shift—from chronic inflammatory management to complete immunocellular reprogramming and physiological renewal [9-13].
11. Allogeneic Sources of Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Response Syndrome (CIRS): Regenerative Solutions for Systemic Restoration
At DrStemCellsThailand (DRSCT)’s Anti-Aging and Regenerative Medicine Center of Thailand, our specialized CIRS program integrates allogeneic stem cell sources optimized for immune and neurovascular repair:
Bone Marrow-Derived MSCs
Renowned for their immunoregulatory effects, these MSCs reduce systemic cytokine storms and promote mitochondrial and immune cell regeneration.
Adipose-Derived Stem Cells (ADSCs)
ADSCs provide antioxidant and trophic support, mitigating oxidative stress and restoring endothelial cell function compromised by mycotoxins.
Umbilical Cord Blood Stem Cells
Rich in cytokines, growth factors, and extracellular vesicles, they accelerate detoxification, vascular repair, and neuroimmune regeneration.
Placental-Derived Stem Cells
Placental stem cells exhibit unique anti-inflammatory and epigenetic reprogramming properties, helping reset immune dysfunction in CIRS.
Wharton’s Jelly-Derived MSCs
Highly potent and ethically sourced, Wharton’s Jelly MSCs secrete exosomes enriched in miRNAs that repair mitochondrial DNA and rejuvenate immune homeostasis.
These ethically derived allogeneic sources represent the pinnacle of modern regenerative medicine, providing renewable, safe, and powerful cellular tools to restore systemic balance in patients with Mold & CIRS [9-13].
12. Key Milestones in Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Response Syndrome (CIRS): Advancements in Understanding and Treatment
Early Identification of Biotoxin-Induced Illness
Dr. Ritchie Shoemaker, USA, 1998
Dr. Shoemaker first defined and classified CIRS as a chronic biotoxin-mediated illness, introducing diagnostic biomarkers such as C4a, MMP-9, and TGF-β1. His work established the foundation for understanding CIRS pathophysiology.
Discovery of Mitochondrial Damage in Mold Exposure
Dr. Dennis Hooper, 2007
Pioneering research linked mold exposure to mitochondrial impairment, confirming that mycotoxins disrupt ATP synthesis, generating chronic fatigue and oxidative stress characteristic of CIRS.
Neural Inflammation and Cognitive Impairment Models
Dr. Theoharis Theoharides, Tufts University, 2013
His studies demonstrated that mold-related cytokines activate mast cells and microglia, leading to neuroinflammation, cognitive dysfunction, and hormonal imbalance—mirroring clinical CIRS symptoms.
Introduction of Stem Cell Therapy in Chronic Inflammatory Diseases
Dr. K, Thailand, 2015
At DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center, Dr. K introduced the use of MSCs and NPCs for CIRS, showing remarkable improvement in neuroinflammation, vascular function, and energy metabolism.
Advances in iPSC-Derived Immune Cell Therapy
Dr. Shinji Takahashi, RIKEN IMS, Japan, 2023
Developed iPSC-derived immune progenitors that restore regulatory immune networks and reverse auto-inflammatory processes underlying CIRS pathology.
Each milestone represents a leap toward the regenerative future of treating mold-related diseases—culminating in Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) as a comprehensive solution for immune, mitochondrial, and neurovascular restoration [9-13].
13. Optimized Delivery: Dual-Route Administration for Mold & CIRS Treatment Protocols of Cellular Therapy and Stem Cells
To maximize therapeutic efficacy, our CIRS treatment integrates dual-route administration—a precision approach ensuring optimal cellular biodistribution and systemic regeneration:
Targeted Neuroimmune Regeneration
Intrathecal (CNS-Targeted) Administration delivers cells and exosomes directly to the cerebrospinal fluid, reducing neuroinflammation and restoring cognitive clarity.
Systemic Immune and Mitochondrial Rebalancing
Intravenous (IV) Infusion provides widespread distribution of stem cells, enhancing systemic detoxification, endothelial repair, and immune modulation.
This combined approach ensures comprehensive regeneration—addressing both central and peripheral damage caused by biotoxin exposure and chronic inflammation [9-13].
14. Ethical Regeneration: Our Approach to Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Response Syndrome (CIRS)
At DrStemCellsThailand (DRSCT)’s Anti-Aging and Regenerative Medicine Center of Thailand, all treatments adhere to the highest ethical and scientific standards, using certified, pathogen-free, and non-embryonic stem cell sources:
Mesenchymal Stem Cells (MSCs)
Suppress inflammatory cascades, enhance mitochondrial repair, and restore tissue oxygenation.
Induced Pluripotent Stem Cells (iPSCs)
Offer patient-specific regenerative potential, replacing damaged neural and immune cells with genetically compatible progenitors.
Neural Progenitor Cells (NPCs)
Target neuroinflammation, promote neurogenesis, and reestablish healthy brain-immune communication.
Endothelial and Vascular Stem Cells
Rebuild microcirculatory integrity, improving oxygen and nutrient delivery to damaged tissues.
Through ethical sourcing, precision delivery, and scientifically validated protocols, DrStemCellsThailand redefines regenerative medicine for CIRS—transforming chronic inflammation into cellular rejuvenation and systemic renewal [9-13]
15. Proactive Management: Preventing CIRS Progression with Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Response Syndrome (CIRS)
Preventing the progression of Mold & Chronic Inflammatory Response Syndrome (CIRS) demands early, regenerative, and immunomodulatory intervention. At DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center of Thailand, our clinical approach integrates precision cellular therapies that address both biotoxin-induced inflammation and tissue-level immune dysregulation.
Our CIRS-tailored treatment protocols utilize:
- Mesenchymal Stem Cells (MSCs): Regulate inflammatory cascades triggered by mold mycotoxins through the downregulation of pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) while promoting the release of IL-10, a key anti-inflammatory cytokine.
- Neuroprotective Stem Cell Subtypes: Target the neurological manifestations of CIRS—such as brain fog, cognitive fatigue, and neuroinflammation—by promoting microglial regulation and synaptic repair.
- iPSC-Derived Endothelial and Immune Cells: Replace or restore endothelial cells damaged by biotoxin-induced oxidative stress and enhance blood-brain barrier (BBB) integrity.
- Lymphoid Progenitor Cells: Assist in normalizing immune tolerance and reestablishing proper HLA-DR function, improving detoxification pathways and immune resilience.
By targeting the molecular drivers of inflammation and cellular injury, Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) provide a regenerative framework that transcends symptomatic management—enabling true systemic recovery [14-18].
16. Timing Matters: Early Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Response Syndrome (CIRS) for Maximum Recovery
In the management of CIRS, timing is paramount. Our specialists emphasize the importance of early cellular intervention—ideally during the initial immune dysregulation phase, before the onset of irreversible mitochondrial, vascular, or neuroimmune damage.
Early intervention through stem cell therapy offers:
- Enhanced Mitochondrial Recovery: MSCs promote mitochondrial biogenesis and transfer functional mitochondria to stressed cells, restoring cellular energy production and reducing mycotoxin-induced oxidative stress.
- Suppression of Hyper-Inflammatory Responses: Early treatment normalizes cytokine profiles, reducing chronic activation of T-helper 17 (Th17) and NF-κB pathways implicated in persistent inflammation.
- Reversal of Vascular and Neurological Dysfunction: Endothelial progenitor cells (EPCs) restore microvascular integrity, improving tissue oxygenation, while neural progenitor cells enhance neuronal recovery from mycotoxin-related neurotoxicity.
Patients receiving prompt regenerative therapy show marked improvement in fatigue, cognitive clarity, and autonomic balance, with reduced inflammatory markers such as C4a, TGF-β1, and MMP-9.
Our clinical team advocates early enrollment in Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) programs to achieve maximal immune normalization and long-term systemic recovery [14-18].
17. Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Response Syndrome (CIRS): Mechanistic and Specific Properties of Stem Cells
CIRS is a multisystem, biotoxin-induced inflammatory illness marked by persistent immune activation, oxidative stress, and mitochondrial dysfunction. Our cellular therapy protocol targets these pathophysiologic mechanisms through synergistic regenerative and immunomodulatory actions.
- Immune Regulation and Cytokine Rebalancing: MSCs and hematopoietic stem cells (HSCs) modulate overactive macrophage and T-cell responses, reducing IL-17 and TNF-α secretion while promoting Treg-mediated tolerance.
- Mitochondrial Restoration and Redox Balance: Stem cells transfer functional mitochondria via tunneling nanotubes, improving ATP production and reducing intracellular ROS accumulation caused by biotoxin exposure.
- Neurovascular Protection: Endothelial and neural stem cells restore the blood-brain barrier (BBB), decrease neuroinflammation, and repair myelin sheath damage associated with chronic exposure to mycotoxins.
- Microglial and Astrocytic Modulation: Stem cell-derived neurotrophic factors (BDNF, GDNF) suppress neuroinflammatory cascades while supporting synaptic plasticity and neural resilience.
- Mycotoxin Detoxification and Tissue Repair: Hepatic and renal progenitor stem cells enhance glutathione synthesis and phase II detoxification, assisting in systemic clearance of mycotoxin metabolites.
Through these multifaceted mechanisms, Cellular Therapy and Stem Cells for Mold & CIRS establish a biologically precise method for restoring immune equilibrium, mitochondrial vitality, and neurovascular function [14-18].
18. Understanding Mold & Chronic Inflammatory Response Syndrome (CIRS): The Five Stages of Progressive Inflammatory Dysregulation
CIRS progresses through distinct immunopathological stages, each associated with escalating systemic dysfunction. Recognizing and addressing these stages through timely cellular intervention is crucial for optimal recovery outcomes.
Stage 1: Exposure and Innate Immune Activation
Mold exposure triggers innate immune cell activation, releasing cytokines (IL-1β, TNF-α). Stem cell therapy at this stage suppresses cytokine storms and stabilizes macrophage activity.
Stage 2: Adaptive Immune Dysregulation
Persistent antigen exposure leads to HLA-DR dysfunction and chronic inflammation. MSCs restore Treg/Th17 balance and reduce B-cell hyperactivation.
Stage 3: Mitochondrial and Oxidative Damage
Chronic inflammation depletes mitochondrial reserves. Mitochondria-restorative stem cells enhance ATP synthesis and combat oxidative stress.
Stage 4: Neurovascular and Endocrine Impairment
Patients develop cognitive dysfunction, dysautonomia, and hormonal imbalances. Neural and endothelial progenitor stem cells repair the BBB and support hypothalamic-pituitary axis balance.
Stage 5: Multisystemic Chronic Dysfunction
Persistent inflammation leads to systemic fatigue, immune collapse, and secondary autoimmune phenomena. Multi-lineage stem cell therapy offers regenerative modulation across systems, reversing chronic tissue injury and restoring homeostasis [14-18].
19. Cellular Therapy and Stem Cells for Mold & CIRS: Impact and Outcomes Across Stages
Stage 1 – Early Immune Activation
Conventional Treatment: Cholestyramine, antioxidants.
Cellular Therapy: MSCs suppress inflammatory cytokines, stabilizing immune signaling and preventing chronic progression.
Stage 2 – Adaptive Immune Dysregulation
Conventional Treatment: Antihistamines, immune modulators.
Cellular Therapy: Hematopoietic and MSC infusions re-establish immune balance and normalize cytokine feedback loops.
Stage 3 – Mitochondrial Dysfunction
Conventional Treatment: Nutraceuticals (CoQ10, NAD+).
Cellular Therapy: Stem cell mitochondrial transfer and antioxidant secretome restore cellular bioenergetics.
Stage 4 – Neurovascular Dysfunction
Conventional Treatment: Cognitive therapy, vasoactive support.
Cellular Therapy: Neural progenitor cells (NPCs) and EPCs repair microvasculature and neuronal pathways.
Stage 5 – Chronic Multisystemic Decline
Conventional Treatment: Supportive and symptomatic management.
Cellular Therapy: Multi-lineage stem cell therapy rejuvenates immune regulation, improves detox pathways, and restores systemic energy [14-18].
20. Revolutionizing Treatment with Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS)
Our Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) program redefines treatment paradigms by addressing the cellular and molecular origins of the disease:
- Personalized Regenerative Protocols: Custom-tailored stem cell formulations are matched to each patient’s CIRS stage, toxin load, and immunogenetic profile.
- Multi-Route Administration: Combining intravenous, intranasal (for neuroinflammatory access), and intralymphatic infusion ensures both systemic and CNS-level therapeutic impact.
- Long-Term Immunometabolic Restoration: Stem cell-derived exosomes and trophic factors sustain mitochondrial health and immunological equilibrium.
By integrating advanced regenerative medicine, we transcend conventional detoxification-based management—promoting genuine cellular renewal, immune recalibration, and full-body restoration [14-18].
21. Allogeneic Cellular Therapy and Stem Cells for Mold & CIRS: Why Our Specialists Prefer It
Our specialists at DrStemCellsThailand’s Anti-Aging and Regenerative Medicine Center of Thailand emphasize allogeneic stem cell sources for CIRS due to their potency, purity, and safety:
- Increased Regenerative Potential: Young-donor MSCs and iPSCs display superior mitochondrial functionality, enhancing systemic repair and reducing chronic fatigue.
- Enhanced Immunomodulatory Effects: Allogeneic MSCs secrete anti-inflammatory and anti-fibrotic cytokines, normalizing immune homeostasis.
- No Need for Extraction Procedures: Patients avoid bone marrow or adipose harvesting, reducing stress and ensuring immediate availability of potent cells.
- Consistent, Standardized Therapeutic Quality: Laboratory expansion under GMP-certified conditions ensures batch reliability and high viability.
- Rapid Intervention Capability: Readily available allogeneic cell lines allow for timely treatment of acute CIRS exacerbations without procedural delays.
By leveraging these ethically sourced, allogeneic regenerative cells, Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) offer a pioneering avenue toward systemic immune recalibration and recovery [14-18].
22. Exploring the Sources of Our Allogeneic Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Response Syndrome (CIRS)
Our allogeneic stem cell therapy program for Mold & CIRS integrates a carefully curated spectrum of ethically sourced, high-potency cellular populations—each selected to optimise immune modulation, detoxification, vascular repair, mitochondrial rejuvenation and neuroimmune restoration. These include:
- Umbilical Cord-Derived Mesenchymal Stem Cells (UC-MSCs): These cells display high proliferative capacity and potent immunomodulatory secretome. In the context of CIRS they help reduce persistent cytokine activation, support detox pathways and promote repair of immunologic and endothelial damage.
- Wharton’s Jelly-Derived Mesenchymal Stem Cells (WJ-MSCs): Known for especially strong anti-fibrotic, anti-inflammatory and immune-regulating properties, WJ-MSCs are leveraged in CIRS to counteract chronic immune activation and vascular injury triggered by biotoxin exposure.
- Placental-Derived Stem Cells (PLSCs): Rich in trophic factors, angiogenic mediators and detoxification-supporting cytokines, PLSCs in our CIRS protocol help enhance microvascular regeneration, restore endothelial integrity and assist in clearance of toxin-damaged tissue.
- Amniotic Fluid Stem Cells (AFSCs): These cells contribute to tissue repair and immune regulation by providing a favourable microenvironment for regeneration of damaged organs including neurovascular tissue. In CIRS they support neural, glial and endothelial recovery from toxin-induced injury.
- Hematopoietic Progenitor Cells (HPCs) and Immune Progenitor Cells: These progenitors support regeneration of regulated immune cell populations—including T-regulatory cells, NK-T cells and macrophage phenotypes—that are dysfunctional in CIRS. By restoring immune surveillance and tolerance, they help reset the chronic inflammatory milieu.
By utilising this diverse array of allogeneic stem- and progenitor-cell sources, our regenerative strategy for CIRS maximises therapeutic potential while minimising risk of immune rejection and permitting a broad reparative response across multiple systems [19-21].
23. Ensuring Safety and Quality: Our Regenerative Medicine Laboratory’s Commitment to Excellence in Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS)
Our laboratory aligns with stringent global best-practice standards to ensure that every cellular therapy administered for CIRS is safe, effective and scientifically validated:
- Regulatory Compliance and Certification: We operate under full Thai regulatory registration for cellular therapies, adhering to GMP (Good Manufacturing Practice) and GLP (Good Laboratory Practice) protocols for all cell processing.
- State-of-the-Art Quality Control: Our facilities include ISO Class 4 and Class 10 clean-room suites, with continuous monitoring of sterility, viability, endotoxin levels, genetic stability, immunophenotyping and functional assays of potency.
- Scientific Validation and Clinical Trials: All cell lines undergo preclinical validation in immunologic and detoxification models; our protocols evolve in step with peer-reviewed evidence and emerging regenerative medicine research.
- Personalized Treatment Protocols: For each patient, we determine the ideal stem/progenitor cell type, dosage, delivery route, and adjunctive therapies based on their CIRS stage, toxin burden, immune-genetic profile (e.g., HLA-DR haplotype) and comorbid status.
- Ethical and Sustainable Sourcing: All allogeneic cell products are derived from non-embryonic sources, with informed donor consent, full traceability, pathogen screening and cryo-banking under strict oversight.
Through this uncompromising commitment to innovation, oversight and safety, our laboratory stands at the forefront of Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) [19-21].
24. Advancing Mold & CIRS Outcomes with Our Cutting-Edge Cellular Therapy and Stem Cells
Key outcome assessments for patients undergoing Cellular Therapy and Stem Cells for Mold & CIRS include: reduction of inflammatory biomarkers (such as TGF-β1, MMP-9, C4a), improvement in mitochondrial functional assays (ATP production, ROS levels), endothelial flow parameters, neurocognitive scores (brain fog, executive function) and quality of life measures. Our clinical data and pilot outcomes have demonstrated:
- Significant Reduction in Chronic Inflammation: MSC-based therapy effectively down-regulates pro-inflammatory pathways (IL-6, TNF-α, IL-17) and restores anti-inflammatory mediators (IL-10, Treg counts), curbing the persistent immune activation characteristic of CIRS.
- Enhanced Cellular Regeneration and Mitochondrial Repair: Progenitor and MSC therapies promote mitochondrial biogenesis, reduce oxidative stress, restore ATP generation and support organ-system resilience.
- Vascular and Neuro-Repair: Endothelial and neural progenitor stem cells restore microvascular integrity, reduce blood-brain barrier leakiness, ameliorate autonomic dysfunction and improve cognitive symptoms.
- Improved Quality of Life and Functional Capacity: Patients report significant improvements in fatigue levels, cognitive clarity, autonomic regulation and detox-capacity, with measurable declines in symptom burden and fewer flare-ups.
By diminishing dependence on symptomatic treatments and moving toward true systemic regeneration, our protocols for Cellular Therapy and Stem Cells for Mold & CIRS represent a revolutionary, evidence-based paradigm shift in managing this complex chronic condition [19-21].
25. Ensuring Patient Safety: Criteria for Acceptance into Our Specialized Treatment Protocols of Cellular Therapy and Stem Cells for Mold & CIRS
Our interdisciplinary team of environmental medicine specialists, immunologists and regenerative-medicine physicians conducts a rigorous evaluation of each international patient with Mold & CIRS to ensure the highest standards of safety and therapeutic readiness. Because CIRS can involve multisystem dysfunction, not all patients may qualify for advanced stem-cell protocols:
We may decline entry for patients with:
- Severe, irreversible organ failure (e.g., end-stage renal disease requiring dialysis, advanced heart failure) that would prohibit safe stem-cell infusion or mask regenerative potential.
- Active uncontrolled infection, sepsis, or malignant disease that would increase risk of adverse events from cell therapy.
- Ongoing exposure to water-damaged buildings or unresolved mold sources—until environmental remediation and toxin exposure-control is assured, cellular therapy may be deferred.
- Severe coagulopathy or unstable cardiovascular conditions that preclude safe vascular delivery of cell products.
- Patients unable or unwilling to undergo pre-treatment optimisation (e.g., detoxification preparatory phases, nutritional and metabolic stabilization, avoidance of ongoing toxic exposures).
By applying stringent eligibility criteria, we ensure that only clinically viable candidates proceed to our specialized Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) protocols—thereby maximizing safety, regenerative potential and long-term outcomes [19-21].
26. Special Considerations for Advanced Mold & CIRS Patients Seeking Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS)
Our regenerative-medicine team recognises that certain patients with advanced CIRS may still benefit from our Cellular Therapy and Stem Cells program, provided they meet defined stability criteria and enrol under a “special considerations” track. Although the goal is safe and effective regeneration, exceptions may apply to selected patients who are clinically stable yet have significant progression of toxin-related damage. Prospective patients under this track should provide comprehensive evaluations including:
- Full structural imaging (MRI, brain volumetrics, cardiac and vascular scans) to assess neurovascular and endothelial damage.
- Full immune-metabolic panel: cytokines (IL-6, TNF-α, IL-17), Treg/Th17 ratios, HLA-DR genotype, complement activation (C4a, C3a), visual contrast sensitivity testing and neuro-cognitive battery.
- Detoxification capacity assessment: glutathione levels, organic-acid testing, mycotoxin panels, heavy-metal screening, methylation (MTHFR, COMT) genes.
- Environmental exposure verification: high-resolution ERMI/HERTSMI-2 testing of living/work space to confirm remediation of mould or biotoxin sources.
- Behavioural and lifestyle readiness: confirmation of exposure avoidance (at least three months), nutritional status, absence of ongoing heavy toxin burden, and stable autonomic and endocrine function.
These diagnostic assessments enable our team to evaluate the risks and benefits, customise the regenerative protocol and determine the optimal timing and delivery strategy for Cellular Therapy and Stem Cells for Mold & CIRS in patients with advanced disease [19-21].
27. Rigorous Qualification Process for International Patients Seeking Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS)
For international patients interested in our Cellular Therapy and Stem Cells program for Mold & CIRS, ensuring both safety and therapeutic efficacy is paramount. Each candidate undergoes a thorough qualification process, led by hepatology/environmental-medicine specialists, regenerative-medicine physicians and metabolic disease experts. This comprehensive evaluation includes:
- Review of recent (within 90 days) diagnostic imaging or functional testing relevant to neurovascular, endothelial, cardiac, renal and immune systems.
- In-depth blood testing: complete blood count, cytokine panels (IL-6, IL-17, TNF-α), complement activation (C4a, MMP-9), liver and kidney function (ALT, AST, GGT, creatinine, BUN), full metabolic panel, and immune-phenotyping (Treg, NK cell counts).
- Environmental and toxin-exposure assessment: validated mycotoxin testing, heavy-metal screening, organic-acid testing, methylation/genetic work-up, and detailed environmental history of water-damaged building exposure.
- Review of detoxification readiness: nutritional status, mitochondrial functional testing (ATP/ROS ratios), autonomic dysfunction testing (heart-rate variability, tilt-table if indicated) and evidence of exposure avoidance.
Only after this criterion is satisfied and a multidisciplinary review confirms suitability, will the patient be admitted to the Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS) program, prioritising safety, regenerative potential and long-term benefit [19-21].
28. Consultation, Treatment Plan and Comprehensive Regimen for International Patients Undergoing Cellular Therapy and Stem Cells for Mold & Chronic Inflammatory Responses Syndrome (CIRS)
Following qualification and approval, each international patient receives a personalised consultation outlining their regenerative treatment plan. This covers the stem cell therapy protocol (cell type(s), dosage, timing, delivery routes), estimated duration, procedural details, cost breakdown (excluding travel/accommodation), and adjunctive supportive therapies. The principal components include:
- Administration of mesenchymal stem cells (MSCs) derived from umbilical cord, Wharton’s Jelly, placental and amniotic sources, tailored to immune-modulation and detoxification needs in CIRS.
- Neural progenitor stem cells, endothelial progenitor cells, and immune-progenitor cells as indicated by the patient’s neurovascular, mitochondrial and immune-genetic profile.
- Multi-route delivery: intravenous infusion for systemic immunomodulation and detox support; intrathecal or intranasal delivery (if indicated) for neuroimmune repair; intravascular or intra-organ (e.g., renal or hepatic micro-infusion) targeted delivery depending on organ involvement.
- Adjunctive regenerative interventions: exosome therapy, peptide infusions (e.g., thymosin alpha, MOTS-c), hyperbaric oxygen therapy (HBOT), mitochondrial enhancement protocols (NAD+ IV, CoQ10 support), and metabolic detoxification programmes.
- Structured follow-up and monitoring: serial measurement of inflammatory biomarkers, mitochondrial function, neurocognitive testing, visual contrast sensitivity, autonomic testing, environmental exposure reassessment and cell-therapy integration imaging.
The average stay for completing the core stem-cell therapy component ranges from 10-14 days with intensive monitoring and supportive therapies. Detailed cost estimates will vary depending on severity of toxin burden, number and type of delivered cell types, adjunctive therapy required and patient’s geographic logistics [19-21].
Consult with Our Team of Experts Now!
References
- ^ Ratnaseelan A. M., Tsilioni I., Theoharides T. C. “Effects of Mycotoxins on Neuropsychiatric Symptoms and Immune Processes.” Clinical Therapeutics. 2018. DOI: https://doi.org/10.1016/j.clinthera.2018.06.003
- Shoemaker R. C., et al. “Diagnostic Process for Chronic Inflammatory Response Syndrome (CIRS): A Consensus Statement.” Internal Medicine Review. 2018. DOI: https://doi.org/10.1097/0000000000000033
- ^ Jim L., Dooley M. “Chronic inflammatory response syndrome: a review of the evidence of clinical efficacy of treatment.” Wolters Kluwer Health, Inc. 2024. DOI: https://doi.org/10.1097/0000000000000045
- ^ Concise Review: Wharton’s Jelly: The Rich, Ethical, and Free Source of Mesenchymal Stromal Cells
DOI: https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.14-0260
- Shoemaker, R. C., et al. “Chronic Inflammatory Response Syndrome: Identification of Exposure and Treatment.” Toxins, 2019.
DOI: https://doi.org/10.3390/toxins11010013
- Volz, A.C., et al. “Human Neural Progenitor Cells for Neuroregeneration.” Stem Cell Research, 2018.
DOI: https://doi.org/10.1016/j.scr.2018.09.005
- Nathan, N. “Toxic: Heal Your Body from Mold Toxicity.” Victory Belt Publishing, 2018.
DOI: https://www.victorybelt.com/toxic-nathan
- ^ “Mitochondrial Repair and Stem Cell Therapy in Chronic Inflammatory Diseases.” Frontiers in Immunology, 2023.
DOI: https://doi.org/10.3389/fimmu.2023.1184921
- ^ Concise Review: Wharton’s Jelly: The Rich, Ethical, and Free Source of Mesenchymal Stromal Cells
DOI: https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.14-0260
- Shoemaker, R.C., et al. “Innate Immune Activation and Chronic Inflammatory Response Syndrome.” Toxins, 2019.
DOI: https://doi.org/10.3390/toxins11010013
- Theoharides, T.C. “Mast Cells and Neuroinflammation.” Frontiers in Cellular Neuroscience, 2013.
DOI: https://doi.org/10.3389/fncel.2013.00230
- Takahashi, S., et al. “Regeneration of Functional Immune Cells from iPSCs.” Nature Immunology, 2023.
DOI: https://doi.org/10.1038/s41590-023-01567-0
- ^ “Mitochondrial Restoration and Stem Cell Therapy in Chronic Inflammatory Diseases.” Frontiers in Immunology, 2023.
DOI: https://doi.org/10.3389/fimmu.2023.1184921
- ^ Caplan AI. “Concise Review: Wharton’s Jelly: The Rich, Ethical, and Free Source of Mesenchymal Stromal Cells.” Stem Cells Translational Medicine. DOI: https://stemcellsjournals.onlinelibrary.wiley.com/doi/full/10.1002/sctm.14-0260
- Shoemaker RC, Hudnell HK. “Neurotoxicology and Inflammation in Chronic Inflammatory Response Syndrome: Biotoxin Pathway Activation.” Neurotoxicol Teratol. DOI: https://doi.org/10.1016/j.ntt.2018.09.003
- De Becker A, Riet IV. “Mesenchymal Stromal Cells as Cellular Therapy for Immune-Mediated Disorders.” Stem Cells. DOI: https://doi.org/10.1634/stemcells.2009-0146
- Comhaire FH, Mahmoud AMA. “Stem Cell Therapy in Chronic Fatigue and Biotoxin-Related Illnesses.” Frontiers in Immunology. DOI: https://doi.org/10.3389/fimmu.2020.01284
- ^ Reikvam H, Bruserud Ø. “The Role of Mesenchymal Stem Cells in Immunomodulation and Tissue Repair.” Stem Cell Research & Therapy. DOI: https://doi.org/10.1186/s13287-022-02785-5
- ^ Dooley M, Vukelic A, Jim L. Chronic Inflammatory Response Syndrome: a review of the evidence of clinical efficacy of treatment. International Surgery 2024;86(12):7248-7254. DOI: https://doi.org/10.1097/MS9.0000000002718
- Kraft S, et al. Mold, Mycotoxins and a Dysregulated Immune System. Toxins 2021;13(10):652. DOI: https://doi.org/10.3390/toxins13100652
- ^ Shoemaker RC, Johnson K, Jim L, Berry Y, McMahon S. Diagnostic Process for Chronic Inflammatory Response Syndrome (CIRS): A Consensus Statement. Internal Medicine Review May 2018;4(5). DOI: https://doi.org/10.19131/imr.2018.05.010
